RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells. PURPOSE: Phase III trial to study the effectiveness of high-dose combination chemotherapy, peripheral stem cell transplantation, and interleukin-2 in treating patients who have acute myeloid leukemia.

Condition	Treatment or Intervention	Phase
adult acute myelomonocytic leukemia (M4) untreated adult acute myeloid leukemia adult acute monocytic leukemia (M5) adult acute myeloblastic leukemia without maturation (M1) adult acute myeloblastic leukemia with maturation (M2) adult acute minimally differentiated myeloid leukemia (M0) secondary acute myeloid leukemia adult acute megakaryocytic leukemia (M7) adult acute erythroleukemia (M6)	Procedure: chemotherapy  Procedure: biological response modifier therapy  Procedure: radiation therapy  Procedure: peripheral blood stem cell transplantation  Procedure: cytokine therapy  Procedure: interleukin therapy  Drug: bone marrow ablation with stem cell support  Drug: cyclophosphamide  Drug: cytarabine  Drug: etoposide  Drug: filgrastim  Drug: idarubicin  Drug: interleukin-2  Drug: melphalan	Phase III

Further Study Details: 

OBJECTIVES: I. Determine relapse free survival of patients with previously untreated de novo or secondary acute myeloid leukemia treated with high dose cytarabine and idarubicin induction, high dose etoposide and cyclophosphamide intensification, filgrastim (G-CSF), melphalan, radiotherapy, autologous peripheral blood stem cell (PBSC) transplantation, and interleukin-2. II. Correlate remission rate and relapse free survival with multidrug resistance phenotype in patients treated with this regimen. III. Determine stem cell content and presence of cells with leukemia specific markers in PBSC harvested following high dose etoposide and cyclophosphamide intensification. IV. Correlate NK cell expansion (an increase in both proportion and absolute number) during interleukin-2 therapy following autologous PBSC transplantation with disease free survival.

PROTOCOL OUTLINE: Induction: Patients receive cytarabine IV over 1 hour every 12 hours for 6 days and idarubicin IV over 30 minutes following third, fifth, and seventh doses of cytarabine. Beginning 12 hours after the last dose of cytarabine, patients receive filgrastim (G-CSF) subcutaneously (SQ) each day until blood counts recover. Intensification: Patients receive etoposide IV over 34.3 hours followed 1 hour later by cyclophosphamide IV over 2 hours for 3 days. Beginning 24 hours after the last dose of cyclophosphamide, patients receive G-CSF SQ each day until blood counts recover. Peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells. Patients receive melphalan IV over 1 hour on day -4 followed by total body irradiation on days -3, -2, and -1. PBSC are reinfused on day 0. When blood counts recover, patients receive high dose interleukin-2 SQ on days 1-10 followed by low dose interleukin-2 SQ on days 11-13. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with immunologic response to 6 courses of interleukin-2 treatment may continue for 6 additional courses.

PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study over 5 years.

Ages Eligible for Study:  25 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Histologically proven de novo or secondary acute myeloid leukemia with a classification of M0-M2 or M4-M7

• No classification of M3
• No promyelocytic leukemia

Prior medical conditions allowed:

• Myelodysplastic syndromes
• Aplastic anemia
• Paroxysmal nocturnal hemoglobinuria
• Myeloproliferative disorders except Philadelphia chromosome positive chronic myelogenous leukemia

--Prior/Concurrent Therapy--

Biologic therapy: Not specified

Chemotherapy:

• No prior chemotherapy for acute leukemia except hydroxyurea
• Prior chemotherapy allowed for other malignancy or other medical condition

Endocrine therapy: Not specified

Radiotherapy: Prior radiotherapy allowed for other malignancy or other medical condition

Surgery: Not specified

--Patient Characteristics--

Age: Over 25

Performance status: Not specified

Life expectancy: At least 4 weeks

Hematopoietic: Not specified

Hepatic:

• Bilirubin no greater than 2 times normal
• SGOT no greater than 2 times normal
• Alkaline phosphatase no greater than 2 times normal

Renal: Creatinine no greater than 1.5 times normal

Cardiovascular:

• Ejection fraction at least 45%
• No severe cardiovascular disease including myocardial infarction within past 6 months, uncontrolled symptomatic congestive heart failure, angina pectoris, or multifocal cardiac arrhythmias

Other:

• No uncontrolled diabetes mellitus
• No other active malignancy
• No hypersensitivity to E. coli derived drug preparations

New York
      Roswell Park Cancer Institute, Buffalo,  New York,  14263-0001,  United States

Study chairs or principal investigators

Maria R. Baer,  Study Chair,  Roswell Park Cancer Institute   

Study ID Numbers:  CDR0000065406; RPCI-DS-96-48; NCI-G97-1152
Record last reviewed:  April 2003
Last Updated:  October 13, 2004
Record first received:  November 1, 1999
ClinicalTrials.gov Identifier:  NCT00002945
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08